{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:48:33Z","timestamp":1789620513719,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007326","name":"Diakonhjemmet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacl.2025.02.002","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T18:20:18Z","timestamp":1739038818000},"page":"649-658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of lipid-lowering therapies in high-risk patients with inflammatory joint diseases\u2014Insights from a preventive cardio-rheuma clinic"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5876-691X","authenticated-orcid":false,"given":"Eli P.","family":"Sollerud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirik","family":"Ikdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-3291","authenticated-orcid":false,"given":"Anne","family":"Kerola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Grete","family":"Semb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9753","key":"10.1016\/j.jacl.2025.02.002_bib0001","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2025.02.002_bib0002","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"issue":"39","key":"10.1016\/j.jacl.2025.02.002_bib0003","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"issue":"13","key":"10.1016\/j.jacl.2025.02.002_bib0004","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.jacl.2025.02.002_bib0005","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.02.002_bib0006","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"9","key":"10.1016\/j.jacl.2025.02.002_bib0007","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/art.34524","article-title":"Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease","volume":"64","author":"Semb","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jacl.2025.02.002_bib0008","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3899\/jrheum.120621","article-title":"Carotid plaque characteristics and disease activity in rheumatoid arthritis","volume":"40","author":"Semb","year":"2013","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.jacl.2025.02.002_bib0009","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1093\/rheumatology\/keac210","article-title":"All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study","volume":"61","author":"Kerola","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.jacl.2025.02.002_bib0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.jacl.2025.02.002_bib0011","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3899\/jrheum.121302","article-title":"Use of lipid-lowering agents in rheumatoid arthritis: a population-based cohort study","volume":"40","author":"Akkara Veetil","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jacl.2025.02.002_bib0012","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijcard.2018.06.111","article-title":"Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseases","volume":"274","author":"Ikdahl","year":"2019","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.jacl.2025.02.002_bib0013","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1136\/ard.2009.126128","article-title":"Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the apolipoprotein-related Mortality RISk (AMORIS) Study","volume":"69","author":"Semb","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.jacl.2025.02.002_bib0014","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"issue":"8","key":"10.1016\/j.jacl.2025.02.002_bib0015","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.echo.2006.04.020","article-title":"Clinical application of noninvasive vascular ultrasound in cardiovascular risk stratification: a report from the American Society of Echocardiography and the Society of Vascular Medicine and Biology","volume":"19","author":"Roman","year":"2006","journal-title":"J Am Soc Echocardiogr"},{"issue":"6","key":"10.1016\/j.jacl.2025.02.002_bib0016","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1515\/CCLM.2008.159","article-title":"Analytical performance evaluation of the Cobas 6000 analyzer - special emphasis on trueness verification","volume":"46","author":"van Gammeren","year":"2008","journal-title":"Clin Chem Lab Med"},{"issue":"25","key":"10.1016\/j.jacl.2025.02.002_bib0017","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","volume":"37","author":"Nordestgaard","year":"2016","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.jacl.2025.02.002_bib0018","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/clinchem\/41.10.1414","article-title":"National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement","volume":"41","author":"Bachorik","year":"1995","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.jacl.2025.02.002_bib0019","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1161\/01.CIR.89.3.1333","article-title":"Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)","volume":"89","year":"1994","journal-title":"Circulation"},{"issue":"8b","key":"10.1016\/j.jacl.2025.02.002_bib0020","first-page":"B95","article-title":"Standardization of lipid, lipoprotein, and apolipoprotein measurements","volume":"34","author":"Cooper","year":"1988","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.jacl.2025.02.002_bib0021","first-page":"160","article-title":"Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges","volume":"38","author":"Virani","year":"2011","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.jacl.2025.02.002_bib0022","unstructured":"HELFO. Individuell st\u00f8nad til kolesterolsenkende legemidler (PCSK9-hemmere). T\u00f8nsberg: Helfo (siste faglige endring 11. januar 2024) 2020 [Available from: https:\/\/www.helfo.no\/lege\/blaareseptordningen\/individuell-stonad-til-kolesterolsenkende-legemidler-pcsk9-hemmere."},{"issue":"7","key":"10.1016\/j.jacl.2025.02.002_bib0023","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of Evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"issue":"10349","key":"10.1016\/j.jacl.2025.02.002_bib0024","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jacl.2025.02.002_bib0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/eurheartj\/ehaa1011","article-title":"Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study","volume":"42","author":"Schubert","year":"2021","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.jacl.2025.02.002_bib0026","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to Statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jacl.2025.02.002_bib0027","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1136\/annrheumdis-2012-202789","article-title":"Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic","volume":"72","author":"Rollefstad","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jacl.2025.02.002_bib0028","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/2047487315569401","article-title":"EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries","volume":"23","author":"Kotseva","year":"2016","journal-title":"Eur J Prev Cardiol"},{"issue":"7","key":"10.1016\/j.jacl.2025.02.002_bib0029","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1177\/2047487312467870","article-title":"SURF - SUrvey of Risk Factor management: first report of an international audit","volume":"21","author":"Cooney","year":"2014","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2025.02.002_bib0030","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/ehjcvp\/pvab052","article-title":"An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries","volume":"8","author":"Rollefstad","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"8","key":"10.1016\/j.jacl.2025.02.002_bib0031","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.02.002_bib0032","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2021.03.039","article-title":"Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a European Atherosclerosis Society Task Force","volume":"325","author":"Averna","year":"2021","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.jacl.2025.02.002_bib0033","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1136\/annrheumdis-2013-204636","article-title":"Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention","volume":"74","author":"Rollefstad","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jacl.2025.02.002_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201196","article-title":"Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease","volume":"14","author":"Hope","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jacl.2025.02.002_bib0035","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/ehjcvp\/pvy028","article-title":"Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review","volume":"4","author":"Vonbank","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"6","key":"10.1016\/j.jacl.2025.02.002_bib0036","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/acr.21643","article-title":"Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study","volume":"64","author":"De Vera","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"32","key":"10.1016\/j.jacl.2025.02.002_bib0037","first-page":"2473","article-title":"Comprehensive efforts to increase adherence to statin therapy","volume":"38","author":"Vonbank","year":"2017","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jacl.2025.02.002_bib0038","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/jcph.689","article-title":"Mitigating the effects of nonadherence in clinical trials","volume":"56","author":"Shiovitz","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jacl.2025.02.002_bib0039","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","article-title":"Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries","volume":"285","author":"De Backer","year":"2019","journal-title":"Atherosclerosis"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425000078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425000078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:30:08Z","timestamp":1762561808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425000078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1933287425000078"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.02.002","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of lipid-lowering therapies in high-risk patients with inflammatory joint diseases\u2014Insights from a preventive cardio-rheuma clinic","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}